News
EOS imaging: First EOSedge™ Installation in Australia
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, announces the
EOS imaging: First EOSedgeTM Installation in Australia
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
No Brainer Club: Ex-Empfehlung mit +2.409% in 7 Monaten
Cardiff Oncology (WKN: A2P4GU) ist einer der diesjährigen Überflieger an der Nasdaq. Seit ihrem Jahrestief bei 0,70 USD steht für die Aktie eine gigantische Performance von +2.409% in nur sieben
ALPHA MOS : Sweet Ventures invests in BOYDSense
PRESS RELEASE
Sweet Ventures invests in BOYDSense to bring non-invasive glucose monitoring using breath analysis to people with diabetes
Toulouse (France) and Vienna (Austria), October 2nd
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its
Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 - LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced its 2020 half-year results
EOS imaging Reports Its 2020 Half-year Financial Results
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible) (Paris:EOSI), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company
First EOSedgeTM installation in the United States
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces
Lysogene: First Half 2020 Business Update
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provides H1 2020 Business update.
As of 30 June 2020, cash and
EOS Imaging Reports Strong Revenue Growth for Half Year 2020
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Heat Biologics: Erste NBC-Empfehlung mit +1.375% in 5 Monaten
Mit Heat Biologics (WKN: A2JB4Y) kannte die erste Empfehlung des weltweit einzigartig erfolgreichen No Brainer Clubs zuletzt kein Halten mehr. Seit Ende Februar steht eine Kursperformance von
EOS imaging Announces the First EOSedge™ Installation in Germany
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), the leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical
EOS imaging: Availability of the 2019 Annual Financial Report in English
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning
GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Lysogene Announces a Research Collaboration With the Weizmann Institute of Science
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that, following discussions
Digirad Celebrates the 20th Anniversary of the First Commercially Performed Solid-state Nuclear Medicine Scan
Digirad, a leading provider of nuclear imaging and diagnostic expertise, is celebrating the 20th anniversary of the first commercially performed solid-state nuclear medicine image being scanned
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results
Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
Novus Therapeutics Reports First Quarter 2020 Financial Results
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial
Lysogene Announces Presentations at Upcoming Meetings
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the upcoming abstract selected
Lysogene Reports Its Cash Position as of 31 March 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March